- In May 2025, the Rotary Club of Kuala Lumpur DiRaja, in collaboration with local healthcare partners, launched a large-scale initiative in Malaysia to distribute erythropoietin injections to over 300 underprivileged end-stage kidney disease (ESKD) patients nationwide. This program aims to improve treatment adherence and reduce anemia-related complications in vulnerable populations, highlighting the increasing emphasis on equitable access to biologic therapies in emerging markets.
- In March 2024, the U.S. Food and Drug Administration (FDA) approved a record number of 18 biosimilars in a single year, including multiple biosimilars for reference products such as Epoetin Alfa. This surge in biosimilar approvals reflects a favorable regulatory environment and strengthens the global competitive landscape of the EPO drugs market by improving affordability and patient access
- In January 2024, Dr. Reddy’s Laboratories announced the expansion of its biosimilar portfolio with the launch of Epoetin Alfa biosimilar in select European markets. The move aligns with the company’s strategy to capitalize on the growing demand for cost-effective anemia treatments and underscores the biosimilar’s increasing acceptance across key regions
- In December 2023, Pfizer reported positive results from a real-world evidence study demonstrating the comparable efficacy and safety of its Retacrit (epoetin alfa-epbx) biosimilar in managing anemia among chronic kidney disease and oncology patients. The findings are expected to bolster confidence in biosimilar adoption among healthcare providers and support broader utilization in clinical practice
- In November 2023, Biosidus S.A., a leading Latin American biopharmaceutical company, expanded its EPO product line by securing new distribution agreements across Southeast Asia and the Middle East. This development marks a strategic effort to strengthen its international footprint and meet the rising regional demand for erythropoiesis-stimulating agents, particularly in dialysis and cancer care settings
